<DOC>
	<DOCNO>NCT00886769</DOCNO>
	<brief_summary>This study assess initial efficacy safety canakinumab 4 week period patient systemic juvenile idiopathic arthritis ( SJIA ) flare . Response treatment accord adapted American College Rheumatology ( ACR ) Pediatric 30 criterion Day 15 .</brief_summary>
	<brief_title>Single-dose Study Assess Efficacy Canakinumab ( ACZ885 ) Patients With Active Juvenile Idiopathic Arthritis ( SJIA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Confirmed diagnosis systemic juvenile idiopathic arthritis per ILAR definition must occur least 2 month prior enrollment onset disease &lt; 16 year age : Arthritis one joint precede fever least 2 week duration document daily/quotidian least 3 day accompany one following : evanescent nonfixed erythematous rash , generalize lymph node enlargement , hepatomegaly and/ splenomegaly , serositis 2 . Parent 's legal guardian 's write informed consent child 's assent , appropriate , patient 's informed consent ≥ 18 year age 3 . Male female patient age ≥ 2 &lt; 20 year age 4 . Active disease time enrollment define follow : At least 2 joint active arthritis Documented spiking , intermittent fever ( body temperature &gt; 38°C ) least 1 day screen period within 1 week first canakinumab/placebo dose Creactive protein ( CRP ) &gt; 30 mg/L ( normal range &lt; 10 mg/L ) 5 . Naïve canakinumab 6 . Other protocol define inclusion criterion may apply Patients fulfilled one follow criterion eligible inclusion study : 1 . Pregnant nursing ( lactate ) female patient 2 . Female patient reach sexual maturity unless career , lifestyle , sexual orientation preclude intercourse male partner and/or use acceptable method contraception 3 . History hypersensitivity study drug biologics . 4 . Diagnosis active macrophageactivation syndrome ( MAS ) ( Ravelli , MagniManzoni Pistorio 2005 ) within last 6 month 5 . With active recurrent bacterial , fungal viral infection , include patient evidence human immunodeficiency virus ( HIV ) infection , hepatitis B hepatitis C infection 6 . Other protocol define exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Flare</keyword>
	<keyword>arthritis</keyword>
	<keyword>IL-1beta antagonist</keyword>
	<keyword>systemic juvenile idiopathic arthritis</keyword>
	<keyword>Juvenile Rheumatoid</keyword>
	<keyword>Systemic juvenile idiopathic arthritis active flare</keyword>
</DOC>